Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 13/20 | 0.75 |
| ▸ | HTR1D | P28221 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | TOP2A | P11388 | 2/20 | 0.53 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1936498 | 0.98 | NISCH (0.73) | NISCHHTR1DADRA1ALMNARECQL | |
| SCHEMBL18719694 | 0.86 | NISCH (1.00) | NISCHHTR1DADRA1ALMNARECQL | |
| SCHEMBL5476725 | 0.81 | NISCH (0.79) | NISCHHTR1DADRA1ALMNARECQL | |
| SCHEMBL12073506 | 0.76 | NISCH (0.81) | NISCHHTR1DADRA1ALMNARECQL | |
| SCHEMBL1685409 | 0.76 | NISCH (0.66) | NISCHHTR1DADRA1ALMNARECQL | |
| SCHEMBL1886692 | 0.76 | NISCH (1.00) | NISCHHTR1DADRA1ALMNARECQL | |
| SCHEMBL771337 | 0.72 | NISCH (0.66) | NISCHHTR1DADRA1ALMNARECQL | |
| SCHEMBL17826831 | 0.72 | NISCH (0.66) | NISCHHTR1DADRA1ALMNARECQL | |
| SCHEMBL2518908 | 0.72 | NISCH (0.66) | NISCHHTR1DADRA1ALMNARECQL | |
| SCHEMBL1209074 | 0.72 | NISCH (0.66) | NISCHHTR1DADRA1ALMNARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| EP-2331518-A1 | NEW BRADYKININ B1 ANTAGONISTS | Evotec AG (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010020556-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | NISCH 337/4885HTR1D 271/4885ADRA1A 48/4885 |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | NISCH 317/4885HTR1D 242/4885ADRA1A 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.